Valuation: Fulcrum Therapeutics, Inc.

Market Cap 281M 254M 234M 212M 400M 26.4B 412M 2.81B 1.12B 14.11B 1.05B 1.03B 44.92B P/E 2026 *
-5.99x
P/E 2027 * -6.66x
Enterprise Value 281M 254M 234M 212M 400M 26.4B 412M 2.81B 1.12B 14.11B 1.05B 1.03B 44.92B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.65%
Yield 2026 *
-
Yield 2027 * -
1 day-1.60%
Current month-0.81%
1 month-1.87%
3 months-1.08%
6 months-47.13%
Current year-67.46%
1 week 3.68
Extreme 3.68
3.76
1 month 3.63
Extreme 3.63
3.8
Current year 2.83
Extreme 2.83
12.03
1 year 2.83
Extreme 2.83
15.74
3 years 2.32
Extreme 2.315
15.74
5 years 2.25
Extreme 2.25
24.79
10 years 2.25
Extreme 2.25
33.1
Manager TitleAgeSince
Chief Executive Officer 59 01/07/2023
Director of Finance/CFO 64 07/08/2023
Chief Tech/Sci/R&D Officer 63 01/12/2022
Director TitleAgeSince
Director/Board Member 71 19/07/2016
Director/Board Member 71 19/07/2016
Chairman 50 10/01/2022
Date Insider Type Main position Quantity % Market Cap. Importance
17/07/26
Tang Capital Management LLC
BuyCompany 50,945 0.0765%
15/07/26
Tang Capital Management LLC
BuyCompany 107,377 0.1611%
13/07/26
Tang Capital Management LLC
OtherCompany 6,663,383 10.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-1.60%0.00%-55.98%+5.14% 285M
+1.10%-2.67%+62.79%+70.47% 67.53B
+1.28%+8.71%+13.96%+95.16% 60.74B
+0.36%-0.95%+20.09%+99.04% 55.66B
-0.96%+7.41%+10.20%+108.91% 47.97B
-1.25%+2.35%+22.74%+38.34% 45.24B
-2.41%-0.73%+167.89%+794.72% 39.08B
+1.21%-2.56%+20.27%+52.81% 35.34B
-0.87%-2.89%+79.60%+63.96% 33.45B
-2.22%+8.56%-39.26%+397.14% 26.49B
Average -0.54%+2.94%+30.23%+172.57% 41B
Weighted average by Cap. -0.17%+3.39%+40.33%+166.58%

Financials

2026 *2027 *
Net sales - -
Net income -47.04M -42.54M -39.27M -35.54M -67.07M -4.42B -69.08M -471M -187M -2.36B -177M -173M -7.53B -44M -39.79M -36.73M -33.24M -62.73M -4.14B -64.61M -441M -175M -2.21B -165M -162M -7.04B
Net Debt - -
Projected Income Statement - Annual - Fulcrum Therapeutics, Inc.
Logo Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. In addition to its product candidates, the Company has developed a discovery approach to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. It also presented preclinical data for FTX-6274, an oral EED inhibitor candidate, demonstrating tumor growth inhibition in castration resistant prostate cancer models.
Employees
9
Date Price Change Volume
12/11/26 $3.680 -1.60% 2,139,186
11/11/26 $3.740 +0.54% 881,425
10/11/26 $3.720 0.00% 932,214
09/11/26 $3.720 +0.54% 1,295,903
06/11/26 $3.700 +0.54% 891,962
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Fulcrum Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
3.680USD
Average target price
3.667USD
Spread / Average Target
-0.36%
  1. Stock Market
  2. Stocks
  3. FULC Stock